Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Role of macrophage targeting in the antitumor activity of trabectedin.

Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P.

Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.

2.

Biology of ovarian cancer and trabectedin mechanism of action.

Ray-Coquard I.

Future Oncol. 2013 Dec;9(12 Suppl):11-7. doi: 10.2217/fon.13.199. Review.

PMID:
24195525
3.

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.

Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, de Braud F, Jimeno J, D'Incalci M.

Cancer Res. 2005 Apr 1;65(7):2964-71.

4.

Trabectedin mechanism of action: what's new?

D'Incalci M.

Future Oncol. 2013 Dec;9(12 Suppl):5-10. doi: 10.2217/fon.13.207. Review.

PMID:
24195524
5.

Trabectedin and ovarian cancer: statistical trickery.

[No authors listed]

Prescrire Int. 2011 Apr;20(115):93. No abstract available.

PMID:
21648209
6.

Trabectedin and ovarian cancer (continued).

[No authors listed]

Prescrire Int. 2011 Oct;20(120):249-50. No abstract available.

PMID:
21970099
7.

Trabectedin in ovarian cancer: could we expect more?

Sessa C, D'Incalci M.

Ann Oncol. 2011 Jan;22(1):7-8. doi: 10.1093/annonc/mdq641. Epub 2010 Nov 8. No abstract available.

8.

Trabectedin has promising antineoplastic activity in high-grade meningioma.

Preusser M, Spiegl-Kreinecker S, Lötsch D, Wöhrer A, Schmook M, Dieckmann K, Saringer W, Marosi C, Berger W.

Cancer. 2012 Oct 15;118(20):5038-49. doi: 10.1002/cncr.27460. Epub 2012 Mar 5.

9.

Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.

Nonaka K, Saio M, Suwa T, Frey AB, Umemura N, Imai H, Ouyang GF, Osada S, Balazs M, Adany R, Kawaguchi Y, Yoshida K, Takami T.

J Leukoc Biol. 2008 Sep;84(3):679-88. doi: 10.1189/jlb.1107729. Epub 2008 Jun 19.

10.

The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.

Mabuchi S, Hisamatsu T, Kawase C, Hayashi M, Sawada K, Mimura K, Takahashi K, Takahashi T, Kurachi H, Kimura T.

Clin Cancer Res. 2011 Jul 1;17(13):4462-73. doi: 10.1158/1078-0432.CCR-10-2987. Epub 2011 May 27.

11.

Trabectedin for the management of soft-tissue sarcoma.

Boudou L, Baconnier M, Blay JY, Lombard-Bohas C, Cassier PA.

Expert Rev Anticancer Ther. 2009 Jun;9(6):727-37. doi: 10.1586/era.09.28. Review.

PMID:
19496709
12.
13.

Introduction. Trabectedin treatment in GYN cancers.

Poveda A.

Int J Gynecol Cancer. 2011 May;21 Suppl 1:S1-2. doi: 10.1097/IGC.0b013e318217b337. Review.

PMID:
21540665
14.

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L.

Blood. 2010 Feb 18;115(7):1461-71. doi: 10.1182/blood-2009-08-237412. Epub 2009 Dec 11.

15.

Trabectedin for the treatment of relapsed ovarian cancer.

Papaioannou D, Rafia R, Stevenson MD, Stevens JW, Evans P.

Health Technol Assess. 2011 May;15 Suppl 1:69-75. doi: 10.3310/hta15suppl1/08. Review.

16.

Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages?

Zhang CH, Xu GL, Jia WD, Ge YS, Wang W.

Hepatogastroenterology. 2010 Jan-Feb;57(97):114-6. Review.

PMID:
20422884
17.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.

Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23.

PMID:
22197612
18.

A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.

Uboldi S, Calura E, Beltrame L, Fuso Nerini I, Marchini S, Cavalieri D, Erba E, Chiorino G, Ostano P, D'Angelo D, D'Incalci M, Romualdi C.

PLoS One. 2012;7(4):e35423. doi: 10.1371/journal.pone.0035423. Epub 2012 Apr 16.

19.

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P.

Cancer Res. 2010 Mar 15;70(6):2235-44. doi: 10.1158/0008-5472.CAN-09-2335. Epub 2010 Mar 9.

20.

The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.

D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, Fusco A.

Eur J Cancer. 2013 Mar;49(5):1142-51. doi: 10.1016/j.ejca.2012.10.014. Epub 2012 Nov 10.

PMID:
23149213
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk